Hemodialysis in hypotensive heart failure using midodrine

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Dialysis is challenging for patients with severe congestive heart failure and hypotension.
• End-stage renal disease patients with symptomatic heart failure often experience low blood pressure during dialysis.
• Midodrine, an alpha (1) agonist, was investigated for its efficacy in managing these complications.

Purpose of the Study:

• To evaluate the effectiveness of midodrine in facilitating outpatient dialysis for patients with heart failure and hypotension.
• To assess the impact of midodrine on blood pressure management and fluid removal during dialysis.
• To determine if midodrine improves heart failure symptoms in dialysis patients.

Main Methods:

• A retrospective study comparing a control period (no midodrine) with a treatment period (midodrine administration before and during dialysis).
• Recorded fluid volume removed, lowest mean arterial pressure (MAP), and postdialysis MAP.
• Analyzed data from 5 patients with end-stage renal disease, heart failure, and hypotension.

Main Results:

• Significant increases in lowest MAP during dialysis and postdialysis MAP (P = 0.03).
• Significant improvement in fluid removal (P = 0.04).
• All patients reported improvement in orthopnea and shortness of breath symptoms.

Conclusions:

• Midodrine administration before and during dialysis is effective in managing hypotension and facilitating outpatient dialysis.
• This approach can relieve congestive heart failure symptoms in elderly patients with poor cardiac function undergoing dialysis.
• Outpatient dialysis becomes a viable option for this high-risk patient group with appropriate pharmacological support.